Differential Efficacy of Treatment with Acetylcholinesterase Inhibitors in Patients with Mild and Moderate Alzheimer’s Disease over a 6-Month Period

By  

Dementia and Geriatric Cognitive Disorders, Vol. 19, Iss. 4, 2005-03 ,pp. : 189-195

Karger

Access to resources Recommend Favorite

A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease

By  

European Neurology, Vol. 44, Iss. 4, 2000-11 ,pp. : 236-241

Karger

Access to resources Recommend Favorite

Galantamine Provides Sustained Benefits in Patients with ‘Advanced Moderate’ Alzheimer’s Disease for at Least 12 Months

By  

Dementia and Geriatric Cognitive Disorders, Vol. 15, Iss. 2, 2003-01 ,pp. : 79-87

Karger

Access to resources Recommend Favorite

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders Extra, Vol. 1, Iss. 1, 2011-06 ,pp. : 163-179

Karger

Access to resources Recommend Favorite

Efficacy of Rivastigmine in Alzheimer’s Disease Patients with Rapid Disease Progression: Results of a Meta-Analysis

By  

Dementia and Geriatric Cognitive Disorders, Vol. 20, Iss. 2-3, 2005-08 ,pp. : 192-197

Karger

Access to resources Recommend Favorite